Long-term relative survival from melanoma in Germany 1997-2013

被引:9
|
作者
Brunssen, Alicia [1 ]
Jansen, Lina [10 ]
Eisemann, Nora [1 ]
Waldmann, Annika [1 ,3 ]
Weberpals, Janick [10 ]
Kraywinkel, Klaus [4 ]
Eberle, Andrea [5 ]
Holleczek, Bernd [6 ]
Zeissig, Sylke R. [7 ]
Brenner, Hermann [8 ,9 ,10 ]
Katalinic, Alexander [1 ,2 ]
机构
[1] Univ Lubeck, Inst Social Med & Epidemiol, Ratzeburger Allee 160, D-23562 Lubeck, Germany
[2] Univ Lubeck, Inst Canc Epidemiol, Lubeck, Germany
[3] Minist Hlth & Consumer Protect, Hamburg Canc Registry, Hamburg, Germany
[4] Robert Koch Inst, German Ctr Canc Registry Data, Berlin, Germany
[5] Leibniz Inst Prevent Res & Epidemiol BIPS, Canc Registry Bremen, Bremen, Germany
[6] Saarland Canc Registry, Saarbrucken, Germany
[7] Canc Registry Rhineland Palatinate, Mainz, Germany
[8] Natl Ctr Tumor Dis NCT, Div Prevent Oncol, Heidelberg, Germany
[9] German Canc Consortium DKTK, Heidelberg, Germany
[10] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany
关键词
histology; melanoma; prognosis; survival; CUTANEOUS MALIGNANT-MELANOMA; UP-TO-DATE; CANCER SURVIVAL; PROGNOSTIC-FACTORS; DEATH CERTIFICATE; POPULATION; TRENDS; AGE; PROPORTIONS; MORTALITY;
D O I
10.1097/CMR.0000000000000482
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(c) 2018 Wolters Kluwer Health, Inc. All rights reserved. Up-to-date melanoma relative survival (RS) estimates and trend analysis facilitate close monitoring of melanoma patients' prognosis. This study aimed to provide recent 5-year and 10-year RS from melanoma, stratified by prognostic factors, and identify latest survival trends. Data from 12 German cancer registries were analysed. We included patients with primary cutaneous malignant melanoma (ICD-10: C43.X) diagnosed in 1997-2013 who were at least 15 years old. Five-year and 10-year RS were estimated by period analysis. For 10-year RS analyses, we excluded patients who were 75 years of age or older. Analyses were stratified by sex, age, histology, tumour stage, and body site. We included 82 901 patients, of whom 51% were women. The median age at diagnosis was 62 years. Five-year and 10-year RS in 2007-2013 were 92.4 and 90.8%, respectively. RS was higher in women. The prognosis worsened with older age and higher stage. In superficial spreading melanoma and lentigo maligna melanoma, RS was high; it was lower in nodular, acral lentiginous and 'other' melanoma. RS was the highest for melanoma on the arms; RS for melanoma on unknown or overlapping sites of the skin was the lowest. Five-year and 10-year RS increased significantly from 2005-2007 and 2008-2010 to 2011-2013, by 3.5 and 3.3 percentage points, respectively. For melanoma of 'other' histology, 5-year and 10-year RS increased significantly. Ten-year RS also increased significantly in men with superficial spreading melanoma and T4 melanoma, and in women with T3 melanoma. Melanoma RS improved, especially in certain subgroups. The reasons for improvements need to be investigated further.
引用
收藏
页码:386 / 395
页数:10
相关论文
共 50 条
  • [41] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
  • [42] Long-term survival and disease regression after adrenalectomy for adrenal metastases from melanoma.
    Collinson, F
    De Bruijn, W
    Lamont, M
    Kefford, R
    De Wilt, J
    Thompson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 720S - 720S
  • [43] Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients.
    Deo, Mugdha Anand
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Bayesian long-term survival model including a frailty term: Application to melanoma data
    Rodrigues, Agatha S.
    Calsavara, Vinicius F.
    Bertolli, Eduardo
    Peres, Stela, V
    Tomazella, Vera L. D.
    CHILEAN JOURNAL OF STATISTICS, 2021, 12 (01): : 53 - 69
  • [45] Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
    Long, G. V.
    Blank, C. U.
    Amaria, R. N.
    Hieken, T. J.
    Sandhu, S. K.
    Barros, M. J.
    Mitchell, T. C. C.
    Eroglu, Z.
    Samoylenko, I. V.
    Rutkowski, P.
    Johnson, D.
    da Silva, I. Pires
    Perry, K. A.
    Tawbi, H. A.
    Block, M. S.
    Ascierto, P. A.
    Burton, E.
    van Akkooi, A. C. J.
    Scolyer, R. A.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1232 - 1232
  • [46] Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013
    Juliusson, Gunnar
    Lazarevic, Vladimir
    Lehmann, Soren
    Derolf, Asa Rangert
    Mollgard, Lars
    Garelius, Hege
    Wennstrom, Lovisa
    Uggla, Bertil
    Antunovic, Petar
    Myhr-Eriksson, Kristina
    Wahlin, Anders
    Hoglund, Martin
    BLOOD, 2014, 124 (21)
  • [47] Longer Survival From Melanoma in Germany
    Eisemann, Nora
    Schumann, Laura
    Baltus, Hannah
    Labohm, Louisa
    Kraywinkel, Klaus
    Katalinic, Alexander
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2024, 121 (02): : 45 - 51
  • [48] Long-term survival data on sentinel lymph node biopsy in anorectal melanoma
    D. C. Damin
    M. A. Rosito
    B. L. Spiro
    Techniques in Coloproctology, 2010, 14 : 367 - 368
  • [49] Long-term survival in stage IV melanoma after repetitive surgical therapy
    Tomov, Tsvetomir
    Siegel, Robert
    Bembenek, Andreas
    ONKOLOGIE, 2008, 31 (05): : 259 - 261
  • [50] Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
    Khammari, Amir
    Knol, Anne-Chantal
    Nguyen, Jean-Michel
    Bossard, Celine
    Denis, Marc-Guillaume
    Pandolfino, Marie-Christine
    Quereux, Gaelle
    Bercegeay, Sylvain
    Dreno, Brigitte
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014 : 186212